-
Thiotepa
- indication:
- pharmacologypharmacology:
- mechanism:
- toxicity:
- absorprion:
- halflife:
- roouteelimination: Urinary excretion of 14C-labeled thiotepa and metabolites in a 34-year old patient with metastatic carcinoma of the cecum who received a dose of 0.3 mg/kg intravenously was 63%.
- volumedistribution:
- clearance: * 446 +/- 63 mL/min [female patients (45 to 84 years) with advanced stage ovarian cancer receiving 60 mg and 80 mg thiotepa by intravenous infusion on subsequent courses given at 4-week intervals]